Remigromig met the non-inferiority endpoint vs ranibizumab in the BRUNELLO DME trial, but PDR adverse events were higher.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results